The Native Antigen Company introduces new range of influenza antigens

  • Season-specific Haemagglutinin and Neuraminidase antigens will support vaccine and diagnostic reformulation programmes
  • New range developed to cover 2023 southern hemisphere flu season

Oxford, UK: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season. The latest influenza antigens will help support development of vaccines and diagnostics as part of the ongoing vaccine reformulation programme, helping to ensure public safety throughout the annual flu season.

In February and September of each year, the World Health Organization (WHO) announces flu vaccine formulations for the northern and southern hemispheres. To support vaccine research and development, The Native Antigen Company has developed Haemagglutinin and Neuraminidase antigens for the WHO-recommended, egg-based and recombinant vaccine strains. Available in bulk quantities, the latest range of antigens can be used in a range of applications, including immunoassay development and as immunogens, and includes reagents for both influenza A and B.

The Native Antigen Company’s influenza antigens were developed using the Company’s proprietary mammalian expression system, VirtueE. The antigen exhibits full glycosylation and folding to ensure that antibodies raised against it are highly specific. The Haemagglutinin antigens feature C-terminal T4 foldon domains, stabilising them in their trimeric conformation to present more native-like conformational epitopes.

Ish Jalal, Commercial Director, The Native Antigen Company, said: Each year, we are proud to be able to support vaccine and diagnostic manufacturers by updating our range of influenza reagents in line with WHO’s guidance. Our customers now have access to the very latest, high-quality antigens for vaccine reformulation, to ensure the public continues to stay safe during the 2023 flu season.”

For further information about The Native Antigen Company’s influenza range, please visit:

For further information please contact:

The Native Antigen Company

Pardeep Sharda

Email: [email protected]

Zyme Communications

Lorna Cuddon

Email: [email protected]

 About The Native Antigen Company

The Native Antigen Company is one of the world’s leading suppliers of reagents that enable research into vaccine development and diagnostics for emerging and endemic infectious diseases. The Native Antigen Company specialises in the development and manufacture of native and recombinant viral and bacterial antigens, antibodies and immunoassays, alongside bespoke product development and custom manufacturing using its proprietary mammalian cell expression system.

The Native Antigen Company’s team have decades of experience in the isolation and purification of native antigens and high-yield mammalian cell expression systems, ensuring conformity to native type. The Company’s high-quality reagents have been widely adopted by leading pharmaceutical, in vitro diagnostic assay manufacturers, and academic groups in cutting-edge vaccine research and serology, where correct folding and glycosylation are vital.

The Native Antigen Company prides itself on an ethical and sustainable approach, exemplified by its use of 100% renewable energy and recycled packaging wherever possible, and building honest and transparent relationships with its customers and collaborators.

Founded in 2010, The Native Antigen Company is located in Oxford (UK) and has a global network of distributors.

Follow The Native Antigen Company on Twitter @nativeantigen and LinkedIn @The Native Antigen Company

About LGC Clinical Diagnostics

LGC’s Clinical Diagnostics Division develops and manufactures a comprehensive portfolio of catalogue and custom-developed diagnostic quality solutions and component materials for the extended life sciences industry. We partner with IVD assay developers, and pharmaceutical, CRO and academic institutions in commercialization activities across the entire diagnostic pipeline – from concept and early stage research, through expedited product development and onwards into routine clinical use. Laboratorians and diagnostic professionals across disciplines of clinical chemistry, immunochemistry, serology, molecular diagnostics and clinical genomics rely on LGC’s products to support accurate and reliable diagnostic results.

Our operating entities include Technopath Clinical Diagnostics, SeraCare Life Sciences and Maine Standards Company, which are in vitro diagnostics (IVD) manufacturers of quality measurement tools (calibrators, controls, linearity, EQA/PT, biological materials). Our 400+ employees operate FDA-registered and ISO 13485-accredited facilities in Tipperary, Ireland, Maine, Massachusetts and Maryland, USA, and an ISO 9001-accredited facility in Oxford, UK. Each day, our world-class staff, scientific expertise, operational efficiency and superior quality systems are ready to support the range of advanced technologies that collectively improve patient outcomes – from the widely adopted and established through to cutting-edge NGS and precision diagnostics.


< | >